Last reviewed · How we verify
NCT05490342
Effect of SARS-CoV-2 Vaccination in Liver Transplant Recipients
trial testing Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples. in SARS-CoV-2 Vaccination in 61 participants. Completed in 30 June 2022.
30 June 2022
Quick facts
| Lead sponsor | University of Rome Tor Vergata |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 61 |
| Start date | 1 April 2022 |
| Primary completion | 30 June 2022 |
| Estimated completion | 30 June 2022 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.
Conditions studied
- SARS-CoV-2 Vaccination — all drugs for SARS-CoV-2 Vaccination →
- Liver Transplantation — all drugs for Liver Transplantation →
Sponsor
University of Rome Tor Vergata
Who can join
18 and older, any sex, with SARS-CoV-2 Vaccination or Liver Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To investigate the variations in the humoral response to vaccines for the prevention of COVID-19 in liver transplant patients based on the type of immunosuppressive therapy adopted (tacrolimus based vs no-tacrolimus based) and immunosuppressive blood levels.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Adjustment of Immunosuppressants to Facilitate Anti-COVID-19 Antibody Production after mRNA Vaccination in Liver Transplant Recipients.
Lee WC, Hung HC, Lee JC, Huang CG, et al · · 2023 · cited 5× · PMID 36992386 · DOI 10.3390/v15030678 -
Evaluation of Humoral Response following SARS-CoV-2 mRNA-Based Vaccination in Liver Transplant Recipients Receiving Tailored Immunosuppressive Therapy.
Manzia TM, Sensi B, Conte LE, Siragusa L, et al · · 2023 · cited 2× · PMID 37959382 · DOI 10.3390/jcm12216913
Verify or expand the search:
- PubMed search for NCT05490342
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Rome Tor Vergata trials
Trials by the same sponsor.
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT07313358 — 10119473 -VIROMARKERS HDV Biomarkers Study · not yet recruiting
- NCT07286461 — VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol · not yet recruiting
- NCT07067749 — Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer · Phase 3 · recruiting
- NCT06711744 — ISQ Differences Between Different Implants in Post-extraction Sockets · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05490342 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Rome Tor Vergata
- Last refreshed: 5 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05490342.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing